191 related articles for article (PubMed ID: 17980571)
1. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy.
Semrau S; Klautke G; Virchow JC; Kundt G; Fietkau R
Respir Med; 2008 Feb; 102(2):210-8. PubMed ID: 17980571
[TBL] [Abstract][Full Text] [Related]
2. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
[TBL] [Abstract][Full Text] [Related]
3. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer -- single institution retrospective analysis.
Lee HW; Choi JH; Lim HY; Park JS; Kim HC; Kang S; Oh YT; Chun M; Sheen SS; Oh YJ; Park KJ; Hwang SC
Neoplasma; 2006; 53(1):30-6. PubMed ID: 16416010
[TBL] [Abstract][Full Text] [Related]
4. 6-year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable non-small cell lung cancer.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Klautke G; Fietkau R
Strahlenther Onkol; 2007 Jan; 183(1):30-5. PubMed ID: 17225943
[TBL] [Abstract][Full Text] [Related]
5. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
6. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
[TBL] [Abstract][Full Text] [Related]
8. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
[TBL] [Abstract][Full Text] [Related]
9. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
McAleer MF; Moughan J; Byhardt RW; Cox JD; Sause WT; Komaki R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):802-8. PubMed ID: 19540055
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.
Fournel P; Robinet G; Thomas P; Souquet PJ; Léna H; Vergnenégre A; Delhoume JY; Le Treut J; Silvani JA; Dansin E; Bozonnat MC; Daurés JP; Mornex F; Pérol M;
J Clin Oncol; 2005 Sep; 23(25):5910-7. PubMed ID: 16087956
[TBL] [Abstract][Full Text] [Related]
11. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
Asmis TR; Ding K; Seymour L; Shepherd FA; Leighl NB; Winton TL; Whitehead M; Spaans JN; Graham BC; Goss GD;
J Clin Oncol; 2008 Jan; 26(1):54-9. PubMed ID: 18165640
[TBL] [Abstract][Full Text] [Related]
12. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience.
Machtay M; Hsu C; Komaki R; Sause WT; Swann RS; Langer CJ; Byhardt RW; Curran WJ
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):667-71. PubMed ID: 15927409
[TBL] [Abstract][Full Text] [Related]
13. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.
Schild SE; Stella PJ; Geyer SM; Bonner JA; McGinnis WL; Mailliard JA; Brindle J; Jatoi A; Jett JR;
J Clin Oncol; 2003 Sep; 21(17):3201-6. PubMed ID: 12874270
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric analysis of the patterns of local failure observed in patients with locally advanced non-small cell lung cancer treated with neoadjuvant chemotherapy and concurrent conformal (3D-CRT) chemoradiation.
Moreno-Jiménez M; Aristu J; López-Picazo JM; Ramos LI; Gúrpide A; Gómez-Iturriaga A; Valero J; Martínez-Monge R
Radiother Oncol; 2008 Sep; 88(3):342-50. PubMed ID: 18558448
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
[TBL] [Abstract][Full Text] [Related]
19. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.
Pourel N; Santelmo N; Naafa N; Serre A; Hilgers W; Mineur L; Molinari N; Reboul F
Eur J Cardiothorac Surg; 2008 May; 33(5):829-36. PubMed ID: 18367406
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials.
Hicks LK; Cheung MC; Ding K; Hasan B; Seymour L; Le Maître A; Leighl NB; Shepherd FA
Cancer; 2009 Dec; 115(23):5516-25. PubMed ID: 19711465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]